Organon
Healthcare therapies and products
- B2B
About Organon
Global healthcare company offering therapies in women’s health, biosimilars, and established medicines to improve everyday health, advising caution against recruitment fraud
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001–10,000 employees
- Headquarters
- Jersey City, New Jersey, United States
- Revenue
- $492M – $3.9BTamtam estimate
- Website
- organon.com
- linkedin.com/company/organon
Organon in the news
- Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)
Organon stock is a merger-arbitrage hold due to an approved acquisition by Sun Pharma at $14.00 per share, with limited upside and weak business fundamentals.
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) is attracting investor interest due to recent stock performance and upcoming earnings estimates.
- Henlius
Henlius signed a deal worth up to $541 million with Organon for the exclusive ex-China commercialization of its HLX11 and HLX14 biosimilar candidates.
- Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Sun Pharma has completed securing $11.75 billion in financing from a syndicate of 11 banks for its acquisition of Organon, aiming to significantly expand its global pharmaceutical market presence.
- Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon shareholders approved the merger with Sun Pharmaceutical Holdings USA, making Organon a wholly owned subsidiary of Sun Pharma USA.
Organon at a glance
Organon is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Jersey City, New Jersey, United States.
Organon has 5,001–10,000 employees.
Organon's revenue is $492M – $3.9B (Tamtam estimate).
Selling to companies like Organon?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies